{"doi":"10.1136/bmj.312.7032.703","title":"Parkinson's disease is rarely a primary cause of death","abstract":null,"journal":"BMJ","year":1996,"id":650310,"datarank":0.37273599746820013,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"self_citation_contribution":0.37273599746820013,"citation_network_contribution":0.0,"self_endowment_contribution":0.37273599746820013,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1695579,"name":"Paul M Watts","orcid":null,"position":1,"is_corresponding":false},{"id":1014349,"name":"Peter Jenner","orcid":"0009-0006-0327-7584","position":2,"is_corresponding":false},{"id":1695578,"name":"Mark T Silva","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Parkinson's disease is rarely a primary cause of death","abstract":"whole, P values at interim analyses would have to be considerably less than 0-01 to achieve significance with any of the common group se- quential designs.3Similarly, confidence intervals reported should be greater than 95%.Thus it is not clear that reports of significance are valid.Finally, levodopa was given to all patients at a daily dose of 375 mg rather than adjusted according to clinical need.Microdialysis studies show that selegiline significantly increases brain dopamine concentrations in rodents after administration of levodopa.4In our study, patients treated with selegiline required significantly less levodopa than patients taking levodopa alone.During the British study the median dose of levodopa was increased to 625 mg in the levodopa group but did not have to be changed in the patients taking levodopa plus selegiline despite their having comparable clinical benefits and increased dopaminergic side effects.Thus patients taking selegiline may have received much more levodopa than necessary, a factor that was related to increased mortality in the Prado study.5We take the British report seriously and will continue to monitor mortality in our patients.Because of the reassuring findings of our study and the increasing evidence of possible neuroprotective benefits related to selegiline, however, we do not recommend that patients should stop taking selegiline on the basis of the results of the British study alone.","is_dataset_classified":null,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"8597747","pmcid":null,"openalex_id":"https://openalex.org/W2072369641","authors":[],"funders":[],"total_grants":0,"fwci":1.231,"citation_percentile":0.80144291,"influential_citations":0,"citation_trend":[{"year":2012,"count":2},{"year":2013,"count":3}],"oa_status":"green","license":"http://www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy","oa_locations":[{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2350542","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2350542","host_type":"repository"},{"url":"http://data.bmj.org/tdm/10.1136/bmj.312.7032.703","host_type":"publisher"},{"url":"https://syndication.highwire.org/content/doi/10.1136/bmj.312.7032.703","host_type":"publisher"},{"url":"https://doi.org/10.1136/bmj.312.7032.703","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/8597747","host_type":"repository"},{"url":"http://www.bmj.com/cgi/content/short/312/7032/703","host_type":"repository"}],"fields_of_study":["Parkinson's Disease Mechanisms and Treatments","Parkinson's Disease and Spinal Disorders","Neurological disorders and treatments","Antiparkinson Agents","Cause of Death","Drug Therapy, Combination","Humans","Levodopa","Parkinson Disease","Selegiline"],"mesh_terms":["Antiparkinson Agents","Cause of Death","Drug Therapy, Combination","Humans","Levodopa","Parkinson Disease","Selegiline"],"keywords":["Disease","Parkinson's disease","Medicine","Primary (astronomy)","Internal medicine"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-10T05:15:30.275259Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}